BiotechTube

FYB201 0.5 mg (0.05 mL of 10 mg/mL)

ApprovedCompleted
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Age-Related Macular Degeneration

Conditions

Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema

Trial Timeline

Jun 11, 2024 → Aug 8, 2024

NCT ID
NCT06708624

About FYB201 0.5 mg (0.05 mL of 10 mg/mL)

FYB201 0.5 mg (0.05 mL of 10 mg/mL) is a approved stage product being developed by Formycon AG for Age-Related Macular Degeneration. The current trial status is completed. This product is registered under clinical trial identifier NCT06708624. Target conditions include Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema.

Hype Score Breakdown

Clinical
30
Activity
20
Company
2
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT06708624ApprovedCompleted

Competing Products

20 competing products in Age-Related Macular Degeneration

See all competitors
ProductCompanyStageHype Score
CLS-AX + Anti-VEGFClearside BiomedicalPhase 1/2
33
CLS-AX + AfliberceptClearside BiomedicalPhase 2
44
Eylea + ALT-L9AlteogenPhase 1
33
FYB203 2 mg (0.05 mL of 40 mg/mL)Formycon AGApproved
77
UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL)Unity BiotechnologyPhase 2
44
DS-7080a + RanibizumabDaiichi SankyoPhase 1
33
Fovista® + bevacizumab + ranibizumab + afliberceptAstellas PharmaPhase 2
52
MA09-hRPEAstellas PharmaPre-clinical
23
volociximabAstellas PharmaPhase 1
33
Avacincaptad PegolAstellas PharmaPhase 1
33
Avacincaptad Pegol + Avastin + Lucentis + EyleaAstellas PharmaPhase 2
52
Avacincaptad PegolAstellas PharmaPhase 1
33
E10030 + ranibizumab + E10030 sham intravitreal injectionAstellas PharmaPhase 3
77
E10030Astellas PharmaPhase 1
33
ASP7317 + tacrolimus + trimethoprim-sulfamethoxazole + Acyclovir + NystatinAstellas PharmaPhase 1
33
Sub-retinal transplantation of MA09-hRPE cells + tacrolimus and mycophenolate mofetil + Placebo tacrolimus and mycophenolate mofetilAstellas PharmaPhase 2
52
Avacincaptad Pegol + LucentisAstellas PharmaPhase 2
52
E10030 + bevacizumab or aflibercept + E10030 sham injectionAstellas PharmaPhase 3
77
Fovista® (anti-PDGF BB) plus anti-VEGFAstellas PharmaPhase 2
52
E10030 plus Lucentis + LucentisAstellas PharmaPhase 2
52

Other Products from Formycon AG

FYB203 2 mg (0.05 mL of 40 mg/mL)Approved
77
FYB206 + FYB206 + KeytrudaPhase 3
69
FYB206 + KeytrudaPhase 1
25